Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | GLA | P06280 | 2/20 | 0.55 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14872275 | 0.82 | KDM4E (0.79) | KDM4EALDH1A1GAAHPGDGLA | |
| SCHEMBL21388420 | 0.66 | MAPK1 (0.46) | KDM4EALDH1A1GAAHPGDGLA | |
| SCHEMBL17403519 | 0.65 | ALDH1A1 (0.40) | KDM4EALDH1A1GAAHPGDGLA | |
| SCHEMBL1791619 | 0.63 | ALDH1A1 (0.38) | KDM4EALDH1A1GAAHPGDGLA | |
| SCHEMBL24126325 | 0.63 | KDM4E (0.40) | KDM4EALDH1A1GAAHPGDGLA | |
| SCHEMBL1794431 | 0.62 | ALDH1A1 (0.37) | KDM4EALDH1A1GAAHPGDGLA | |
| SCHEMBL21590039 | 0.62 | ALDH1A1 (0.41) | KDM4EALDH1A1GAAHPGDGLA | |
| SCHEMBL2199168 | 0.62 | KDM4E (0.55) | KDM4EALDH1A1GAAHPGDGLA | |
| SCHEMBL15492448 | 0.62 | ATM (0.64) | KDM4EALDH1A1GAAHPGDGLA | |
| SCHEMBL8421248 | 0.61 | CA2 (0.50) | KDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | IL4, IL2, IL4I1 | KDM4E 586/4885ALDH1A1 3144/4885GAA 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.